MVP and hepatocellular carcinoma: In HCC cells, overexpression of MVP reduced sensitivity to epidermal growth factor receptor (EGFR) inhibitor gefitinib, enhanced AKT phosphorylation, and lowered the expression of genes associated with inflammatory pathways.